



INTERNATIONAL JOURNAL OF CLINICAL PHARMACOKINETICS AND MEDICAL SCIENCES

Published by Pharma Springs Publication

Journal Home Page:

<https://pharmasprings.com/ijcpms>

Development of innovative standards for the registration of drugs in India based on International norms

Dhamotharan Jothieswari*¹, Vellore Asha², Audinarayana Nelavala³

¹Department of Pharmaceutical Analysis, Sri Venkateswara College of Pharmacy (Autonomous), RV Nagar, Tirupathi Road, Chittoor-517127, Andhra Pradesh, India

²Sri Venkateswara College of Pharmacy (Autonomous), RV Nagar, Tirupathi Road, Chittoor-517127, Andhra Pradesh, India

³Department of Pharmaceutics, Sri Venkateswara College of Pharmacy (Autonomous), RV Nagar, Tirupathi Road, Chittoor-517127, Andhra Pradesh, India

Article History:

Received on: 26 Oct 2023
Revised on: 01 Nov 2023
Accepted on: 02 Nov 2023

Keywords:

Drug registration,
Pharmaceutical sector,
Regulatory framework,
Indian market

Abstract

This research endeavors to pioneer a paradigm shift in drug registration protocols within the Indian pharmaceutical sector, aligning them with internationally recognized norms. The study delves into the imperative need for harmonizing regulatory standards to ensure the safety, efficacy, and quality of pharmaceutical products entering the Indian market. By integrating key benchmarks from global authorities, this initiative aims to foster a robust and transparent registration process, ultimately bolstering consumer trust and industry competitiveness. The research methodology encompasses a comprehensive review of international regulatory frameworks, comparative analysis, stakeholder consultations, and case studies to propose a refined set of standards tailored to the Indian context. Additionally, this study addresses potential challenges and proposes strategies for effective implementation. Through this innovative approach, the research aspires to lay the foundation for a more dynamic and globally integrated pharmaceutical landscape in India, poised for sustained growth and excellence.



*Corresponding Author

Name: Dr.D.Jothieswari
Phone: +91 9989165610
Email: jothies82@gmail.com

eISSN: 2583-0953

DOI: <https://doi.org/10.26452/ijcpms.v3i4.554>



Production and hosted by
Pharmasprings.com
© 2023 | All rights reserved

INTRODUCTION

Before India gained independence in 1947, drug regulation was primarily governed by the British colonial administration. The emphasis was on controlling opium and certain other substances due to their potential for abuse. After independence, the need for a comprehensive drug regulatory framework became apparent [1].

This legislation laid the foundation for drug regulation in India and established the DCGI as the central authority overseeing drug approvals. In

1962, the Indian government introduced the Drug Policy, which aimed to promote the growing of pharmaceutical industry while ensuring availability of essential drugs at reasonable prices. This policy encouraged domestic drug production and reduced reliance on imports. In the late 20th century, globalization brought about significant changes in the pharmaceutical sector. India emerged as a major player in the global generic drug market. However, this growth also posed challenges related to quality control, intellectual property rights, and compliance with international regulatory standards. The adoption of the TRIPS agreement in 1995 as part of the World Trade Organization (WTO) had a profound impact on India's pharmaceutical industry. It required stricter enforcement of IPR, including patents on pharmaceutical products [2]. India's approach to IPR in pharmaceutical sector has been balanced to ensure access to affordable medicines. The country has utilized provisions for compulsory licensing to allow production of generic versions of patented drugs in the interest of public health.

In recent years, Indian government has taken steps to enhance regulatory framework for drugs. This includes the introduction of the New Drugs and Clinical Trials Rules in 2019, aimed at streamlining the approval process for new drugs [3]. Recognizing the need to align with international norms, efforts are underway to develop innovative standards for drug registration in India.

In conclusion, the background and history of India reflect a dynamic evolution in response to changing global and domestic pharmaceutical landscapes. Balancing industry growth, access to medicines, and compliance with international norms remains a critical focus in the ongoing development of drug registration standards in the country [4].

Significance of Drug Registration

Drug registration holds immense significance in the pharmaceutical industry as it serves as a critical gateway to ensure the safety, efficacy, and quality of pharmaceutical products before they are made available to the public. This process involves a comprehensive evaluation of a drug's composition, manufacturing process, and clinical data, conducted by regulatory authorities. This

scrutiny helps to identify potential risks and benefits associated with the drug, ensuring that it meets established standards and guidelines.

Furthermore, drug registration plays a pivotal role in safeguarding public health. It acts as a safeguard against the introduction of substandard or counterfeit drugs into the market, which could pose serious health risks to consumers. By subjecting drugs to rigorous evaluation, regulatory authorities can identify and prevent the distribution of unsafe or ineffective products, ultimately protecting the well-being of patients [5].

Moreover, drug registration promotes transparency and accountability within the pharmaceutical industry. It establishes a clear framework for manufacturers and marketers to adhere to, ensuring that they operate within established legal and ethical boundaries. This fosters trust among stakeholders, including healthcare professionals, patients, and regulatory authorities, who can rely on the fact that registered drugs, have met stringent quality and safety standards.

Additionally, drug registration is integral to fostering innovation and advancement in the field of medicine. It incentivizes pharmaceutical companies to invest in research and development, knowing that their products must meet rigorous regulatory requirements before they can reach the market. This, in turn, drives the development of new and improved treatments, ultimately benefiting patients and advancing medical science.

In summary, the significance of drug registration cannot be overstated. It acts as a vital checkpoint to ensure that pharmaceutical products meet the highest standards of safety, efficacy, and quality. By doing so, it protects public health, promotes industry integrity, and encourages innovation in the pharmaceutical sector [6].

Drug Registration Guidelines in India

Registering a drug in India involves several steps to ensure compliance with the regulatory framework set forth by [7] CDSCO, which is the regulatory authority for pharmaceuticals in India and includes.

Preparation and Submission of Application

Compile all necessary documentation, including data on pre-clinical and clinical trials, chemistry,

manufacturing, and controls (CMC), and other relevant information.

Prepare the application in the required format as per Schedule D of Dc act Rules, 1945 [8]. Submit the application along with the required fee to the CDSCO through the appropriate zonal office.

Screening of Application

The CDSCO reviews the application to ensure it is complete and meets the regulatory requirements. If any deficiencies are identified, the applicant will be notified and given a chance to rectify them.

Technical Scrutiny

The CDSCO conducts a detailed review of the submitted data, including pre-clinical and clinical trial results, CMC information, and other relevant documentation [9]. The application is evaluated for scientific and technical aspects, including safety, efficacy, quality, and manufacturing processes.

Expert Committee Evaluation

An expert committee may be convened to review specific aspects of the application, such as clinical data, pharmacovigilance, or other specialized areas. The committee provides recommendations to the CDSCO based on their evaluation.

Inspection of Manufacturing Facilities (if required)

The CDSCO may conduct inspections of the applicant's manufacturing facilities to ensure compliance with GMP and other quality standards [9]. A satisfactory inspection report is crucial for the approval process.

Generation of Unique Identification Number (UIN)

Once the application is deemed satisfactory, a Unique Identification Number (UIN) is generated for tracking purposes.

Review and Approval by CDSCO

The CDSCO reviews all the information and recommendations from the technical scrutiny, expert committee, and inspection reports (if applicable) [10]. Based on the evaluation, the CDSCO may grant or reject the registration.

Issue of Registration Certificate

If the application is approved, the CDSCO issues a Registration Certificate (Form 41) to the applicant.

Post-Approval Compliance

The applicant must comply with all post-approval requirements, including pharmacovigilance, reporting of adverse events, and any other specific conditions set forth in the registration.

Renewal of Registration

The registration of a drug is typically valid for a specific period, after which it needs to be renewed. The applicant must apply for renewal before the expiration date [11]. It is essential to note that this is a general outline, and specific requirements may vary depending on factors such as the type of drug, its classification, and any special considerations for certain therapeutic categories. Additionally, it is crucial to consult with regulatory experts or legal counsel with expertise in pharmaceutical registration in India to ensure full compliance with current regulations and requirements.

DISCUSSION

The growth of innovative standards for registration of drugs in India based upon international norms represents a pivotal advancement in the country's pharmaceutical landscape. This endeavor stems from the recognition that aligning Indian regulatory practices with globally accepted standards is crucial for fostering a competitive and reputable pharmaceutical industry. By doing so, India not only ensures the safety, efficacy, and quality of pharmaceutical products but also enhances its standing in the global market [12].

One significant aspect of this initiative lies in its potential to streamline and expedite the drug registration process. Through the adoption of international best practices, bureaucratic hurdles and redundancies within the existing framework can be minimized. This, in turn, facilitates a more efficient pathway for innovative drugs to reach the market, benefiting both patients and the pharmaceutical industry [13].

Furthermore, the integration of international norms in drug registration bolsters confidence in the Indian pharmaceutical sector among global stakeholders. International partners, investors,

and consumers gain assurance that products from India meet the highest international standards. This confidence is instrumental in encouraging foreign investment and expanding export opportunities, ultimately contributing to the growth and sustainability of the Indian pharmaceutical industry [14].

Additionally, the emphasis on international norms signifies a commitment to patient safety and public health. Rigorous evaluation processes, in line with global benchmarks, help identify potential risks associated with pharmaceutical products. This proactive approach not only protects consumers from potential harm but also builds trust in the safety of medicines available in the Indian market [15].

The adoption of international norms also facilitates greater harmonization in drug regulations across borders. This standardization not only simplifies the process for multinational pharmaceutical companies but also supports efforts to combat the global issue of counterfeit and substandard drugs. By aligning with international best practices, India contributes to the broader global health agenda, promoting access to safe and effective medicines worldwide [16].

Nevertheless, it is essential to acknowledge that the implementation of innovative standards in drug registration may come with its own set of challenges. These could include the need for enhanced infrastructure, additional training for regulatory personnel, and potential adjustments to existing legal frameworks. However, these challenges are outweighed by the substantial benefits that aligning with international norms can bring to the Indian pharmaceutical industry and public health [17].

In conclusion, the development of innovative standards for drug registration based on international norms is a pivotal step forward for the Indian pharmaceutical sector and also Herbal medicine is used to treat numerous ailments, including diabetes, asthma, hepatoprotective, rheumatoid arthritis, cardio tonic, chronic tiredness, irritable bowel syndrome, and cancer [18][19]. It not only enhances the competitiveness and credibility of the industry but also safeguards public health, promotes global harmonization, and fosters international collaboration. By embracing

these standards, India positions itself as a key player in the global pharmaceutical arena, poised for sustained growth and excellence [20].

CONCLUSION AND SUMMARY

The endeavor towards the development of innovative standards for the registration of drugs in India, rooted in international norms, culminates in a significant leap forward for the nation's pharmaceutical industry. This initiative underscores India's commitment to aligning its regulatory practices with global benchmarks, ultimately ensuring the safety, efficacy, and quality of pharmaceutical products. By integrating international best practices into the registration process, India not only strengthens its pharmaceutical ecosystem but also solidifies its position as a key player in the global market.

The adoption of international norms promises to streamline and expedite the drug registration process, significantly reducing bureaucratic bottlenecks and expediting the approval of innovative drugs. This streamlined approach holds the potential to revolutionize the industry, ensuring that cutting-edge treatments reach patients in a more timely and efficient manner.

Moreover, the convergence towards international standards serves as a powerful signal to the global community that India's pharmaceutical sector is committed to excellence and safety. This renewed confidence from international partners and stakeholders is poised to stimulate further investment and collaboration, driving innovation and growth in the industry.

In the pursuit of international norms, the paramount consideration remains the safety and well-being of patients. The rigorous evaluation processes embedded in global standards serve as a robust defense against potential risks associated with pharmaceutical products. This commitment to patient safety is not only a regulatory imperative but also a testament to India's dedication to providing its citizens with the highest quality of healthcare.

Furthermore, the endeavor towards aligning with international norms reinforces the global fight against counterfeit and substandard drugs. Through standardization, India contributes to a more cohesive and coordinated global effort to

ensure the availability of safe and effective medicines across borders.

While challenges in implementation may arise, including the need for enhanced infrastructure and training, the potential benefits far outweigh these hurdles. The development of innovative standards for drug registration based on international norms signals a transformational shift in India's pharmaceutical landscape, poised to elevate the industry to new heights.

In summary, the pursuit of innovative standards for drug registration in India, grounded in international norms, represents a momentous stride towards excellence, safety, and competitiveness in the global pharmaceutical arena. This initiative epitomizes India's commitment to delivering high-quality healthcare to its citizens and reaffirms its standing as a global leader in pharmaceutical innovation and regulation. By embracing these standards, India not only advances its own pharmaceutical industry but also contributes significantly to the global advancement of public health.

FUTURE PROSPECTS

The future prospects of the development of innovative standards for drug registration in India, aligned with international norms, hold immense promise for the country's pharmaceutical sector. This forward-looking initiative is poised to shape the industry in several significant ways.

Firstly, the adoption of international norms will likely lead to increased global recognition and acceptance of Indian pharmaceutical products. As India consistently demonstrates its commitment to upholding the highest quality and safety standards, it is poised to become a more trusted and reliable supplier of pharmaceuticals on the global stage. This enhanced reputation could open up new markets and export opportunities, driving economic growth in the sector.

Moreover, the alignment with international norms is expected to stimulate greater research and development investments in the Indian pharmaceutical industry. With a more transparent and standardized regulatory environment, pharmaceutical companies are likely to be more inclined to invest in cutting-edge research and innovation. This, in turn, can lead to the development of novel and advanced therapeutic

solutions, positioning India as a hub for pharmaceutical innovation.

Additionally, the introduction of innovative registration standards is likely to foster a culture of continuous improvement and learning within the regulatory agencies. Regular interaction and collaboration with international counterparts will help to keep Indian regulatory authorities updated on the latest advancements and best practices in drug evaluation. This ongoing exchange of knowledge can lead to a more dynamic and adaptive regulatory environment, ensuring that India remains at the forefront of pharmaceutical regulation.

Furthermore, the development of innovative standards can pave the way for enhanced cooperation and partnerships between Indian pharmaceutical companies and global stakeholders. Collaborative ventures in research, development, and manufacturing may become more prevalent as the mutual confidence in regulatory standards grows stronger. These partnerships have the potential to drive synergies, accelerate drug development, and lead to the creation of more effective and accessible healthcare solutions.

In the realm of public health, the adoption of international norms is likely to have a profound impact on patient outcomes. With a more robust and standardized regulatory framework, patients can have greater confidence in the safety and efficacy of the drugs available to them. This assurance can lead to improved treatment adherence and outcomes, ultimately benefiting public health on a national scale.

In conclusion, the future of the development of innovative standards for drug registration in India based upon international norms is marked by the potential for enhanced global recognition, increased research and development activities, collaborative partnerships, and improved patient outcomes. By aligning with international best practices, India is poised to elevate its pharmaceutical industry to new heights, ultimately contributing to the advancement of public health both within the country and on the global stage.

ACKNOWLEDGEMENT

The authors are thankful to the Principal and Management of Sri Venkateswara College of Pharmacy, Chittoor for providing the necessary Guidance to prepare this review work.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Funding Support

The authors declare that they have no funding for this study.

REFERENCES

- [1] K Chakraborty, and K Yadav. Drug approval process in US, Europe and India and its regulatory requirements: A Review. *International Journal of Drug Regulatory Affairs*, 6(3): 31-39, 2018.
- [2] A K Mahapatra, N H Sameeraja and P N Murthy. Drug Approval Process In United States of America, European Union and India : A Review. *AcrcTra*, 1(1):13-22, 2014.
- [3] N Jawahar, and T Vidhya Lakshmi. Regulatory Requirements for the Drug Approval Process in US, Europe and India. *J Pharm Sci and Res*, 9(10):1943-1952, 2017.
- [4] C C Panel. Mandatory registration of clinical trials. *J Am Coll Surg*, 204(4):654-655, 2007.
- [5] N Vishal Gupta, C Mohan Reddy, K Pradeep Reddy, R Ajay Kulkarni, and H G Shivakumar. Process of Approval of New Drug In India With Emphasis on Clinical Trials. *International Journal of Pharmaceutical Sciences Review and Research*, 13(2):17-23, 2012.
- [6] K Lee, P Bacchetti, and I Sim. Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis. *PLoS Med*, 5(9):191-194, 2008.
- [7] A M Sawant, D P Mali, and D A Bhagwat. Regulatory Requirements and Drug Approval Process in India, Europe and US. *Pharmaceut Reg Affairs*, 7(2):1-10, 2018.
- [8] Norman GA Van. *Drugs and Devices*. *JACC Basic to Transl Sci*, 1: 399-412, 2016.
- [9] S M Paul, D S Mytelka, C T Dunwiddie, C C Persinger, B H Munos, S R Lindborg, and A L Schacht. How to improve R and D productivity: The pharmaceutical industry's grand challenge. *Nat Rev Drug Discov*, 9(3):203-214, 2010.
- [10] F Pammolli, L Magazzini, and M Riccaboni. The productivity crisis in pharmaceutical R&D. *Nat Rev Drug Discov*, 10(6):428-438, 2011.
- [11] R D Sanders, and M Maze. Translational research: addressing problems facing the anesthesiologist. *Anesth Analg*, 105(4):899-901, 2007.
- [12] Pravin Amin, Alison Fox-Robichaud, J V Divatia, Paolo Pelosi, Defne Altintas, Emel Eryüksel, Yatin Mehta, Gee Young Suh, Lluís Blanch, Norbert Weiler, Janice Zimmerman, and Jean-Louis Vincent. The Intensive care unit specialist: Report from the Task Force of World Federation of Societies of Intensive and Critical Care Medicine. *J Crit Care*, 35:223-228, 2016.
- [13] J Besso, S Bhagwanjee, J Takezawa, S Prayag, and R Moreno. A global view of education and training in critical care medicine. *Crit Care Clin*, 22(3):539-546, 2006.
- [14] M Imran, A K Najmi, M F Rashid, S Tabrez, and M A Shah. Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go. *J Pharm Bioallied Sci*, 5(1):2-9, 2013.
- [15] S Sariola, D Ravindran, A Kumar, and R Jeffery. Big-pharmaceuticalisation: clinical trials and Contract Research Organisations in India. *Soc Sci Med*, 131:239-246, 2015.
- [16] N J Gogtay, R Ravi, and U M Thatte. Regulatory requirements for clinical trials in India: What academicians need

to know. Indian J Anaesth, 61(3):192-199, 2017.

- [17] K Anitha, S Mohana Lakshmi, and S V Satyanarayana. Antidiabetic, lipid lowering and antioxidant potentiating effect of Canavalia species in high fat diet-streptozotocin induced model. *Advances in Traditional Medicine*, 20(5):609-618, 2020.
- [18] A Kuttiappan, S M Lakshmi, and S V Satyanarayana. Antioxidant potential of ethanolic extract of Canavalia species in high-fat diet and streptozotocin-induced diabetic rats. *Pharmacognosy Research*, 11(4):400-405, 2019.
- [19] P S Bhanu, A Kuttiappan, A A Balaji, N Sambavi, and K Taruna. Review on Some Selected Herbal Plants for its Traditional and Medicinal Uses-A Novel Approach. *Int. J. Pharm Sci Rev Res*, 72(1):35-38, 2022.
- [20] V Muthuswamy. Status of ethical review and challenges in India. *Indian Pediatr*, 42(12):1189-1190, 2005.

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial- Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.



© 2023 Pharma Springs Publication